$ATHE News

Alterity Therapeutics Secures Key US Patent for Lead Asset

Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

Alterity Therapeutics Receives Official Meeting Minutes From Fda End-of Phase-2 Meeting For ATH434 In Multiple System Atrophy; Pivotal Phase 3 Trial Activities On Track To Initiate By End Of 2026

Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

Alterity Therapeutics Presents On Multiple System Atrophy Program Including Its Novel Imaging And Biomarker Approach, Phase 2 Data, And Current Plans To Advance ATH434 Into Phase 3 Clinical Development.

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

Alterity Therapeutics Announces Publication Of Peer-Reviewed Study In NeuroImage Showing QSM MRI Can Detect Disease-Specific Iron Accumulation In Brains Of Patients With MSA

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegenerative Disease With No Approved Disease-Modifying Treatments

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

Alerity Therapeutics Announces Presentation Of New Data Analyses From The Phase 2 Trial Of ATH434, Demonstrating Clinical Efficacy In Patients With Multiple System Atrophy At The American Academy of Neurology Annual Meeting

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

Alterity Therapeutics To Present ATH434 MSA Data At AAN Late‑Breaking Session, April 21; ATH434 Shows Disease‑Modifying Signal In MSA

Alterity Therapeutics To Present ATH434 MSA Data At AAN Late‑Breaking Session, April 21; ATH434 Shows Disease‑Modifying Signal In MSA

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy